The Signature PrenatalChip®TE (Targeted Enhanced) microarray features a unique clinically-relevant targeted design with densely placed oligo probes in areas of recognized genetic syndromes.
This oligo-based design:
- Detects chromosome imbalances expected to be identified by karyotyping
- Offers enhanced capability to detect and characterize chromosome imbalances that are too small to be identified by karyotyping
Suggested prenatal uses for this microarray include cases with:
- Multiple congenital anomalies
- Ultrasound abnormalities with normal karyotype results
- Abnormal maternal serum screen
- Advanced maternal age or parental concern
Signature PrenatalChip®TE features
- Oligonucleotide-based microarray
- Over 37,000 oligo probes
- Targets over 245 clinically recognized genetic syndromes
- Average backbone coverage of one probe every 100 kb to limit the number of unclear results. (View syndromes tested by the Signature PrenatalChip®TE)
- Average of one probe every 10 kb in regions of clinical relevance
Signature PrenatalChip®TE + SNP
SNP microarray analysis can be ordered to run concurrently with the Signature PrenatalChip®TE. SNP microarray testing can provide a level of detection beyond what copy number analysis can provide in the assessment and diagnosis of disorders that may be caused by absence of heterozygosity (AOH).
The suggested uses for the Signature PrenatalChip®TE + SNP microarray include all of the uses listed above, plus:
- Clinical suspicion of risk for AOH-related disorders
- Imprinting-associated disorders*
- Autosomal recessive disorders due to shared parental ancestry
- Clinical suspicion of triploidy
*If an imprinting-associated disorder is the primary diagnosis being considered, other types of testing are more appropriate.
The Signature PrenatalChip®TE + SNP features an average SNP probe spacing of one probe every 40 kb across the genome. This microarray detects contiguous stretches of AOH >= 10 Mb.
Click here to read about the Signature PrenatalChip®OS, another prenatal microarray option.